Navigation Links
Mercury Therapeutics, Inc: Marquant Appointed to Advise on Strategic and Partnering Opportunities
Date:3/17/2008

nds in a glucose tolerance test in mice. In Q4 2006, MTI implemented a chemical design and synthesis program which led to the submission of a patent application in February 2008 claiming two novel lead series of AMPK activators.

MTI is an early stage drug discovery company focusing on the development of small molecule candidates against a number of selected protein kinase drug targets in metabolic diseases and oncology. MTI's main focus is on the discovery and development of orally active small molecule activators of AMPK, a well-validated though largely unexploited, protein kinase drug target in metabolic disease. While a number of anti-diabetic drugs currently on the market, including metformin (Glucophage(R)) and pioglitazone (Actos(R)), act indirectly to activate AMPK, MTI is seeking to develop the first orally available direct AMPK activator. The potential indications of a successful AMPK targeted drug include Type-2 diabetes, hyperlipidemia, obesity, metabolic syndrome and endocrine cancers.

For further information:

Mercury Therapeutics Inc.

Neil C Birnberg, Ph.D, President & CEO Tel: + 1-781-932-1125

birnberg@mtipharm.com http://www.mtipharm.com


'/>"/>
SOURCE Mercury Therapeutics Inc.
Copyright©2008 PR Newswire.
All rights reserved

0

GOOD

Page: 1 2 3

Related biology technology :

1. Mercury Therapeutics, Inc: Lead Series of Indirect AMPK Activators Licensed to Makoto Life Sciences
2. Systems Medicine (SM), a Subsidiary of Cell Therapeutics, Inc. (CTI), Announces Execution of CRADA with NCI/NIH to Develop Potential Cancer Treatments Targeting the Insulin Growth Factor (IGF) Pathway
3. Cell Therapeutics, Inc. Takes Corrective Actions in Response to Nasdaq Determination
4. ARYx Therapeutics, Inc. Files Registration Statement for Initial Public Offering
5. Nile Therapeutics, Inc. Adds to Executive Management Team
6. Cell Therapeutics, Inc. (CTI) Receives SPA Approval from FDA and Launches Gender-Specific Phase III Trial for Advanced Non-Small Cell Lung Cancer
7. Founder of ILEX Oncology and Triton Biosciences, Richard Love, Joins Board of Directors of Cell Therapeutics, Inc. (CTI)
8. Cell Therapeutics, Inc. (CTI) Announces 2007 Annual Shareholders Meeting Results
9. Northwest Biotherapeutics, Inc. Announces Appointment of Chief Financial Officer
10. Nile Therapeutics, Inc. to Present at Upcoming BIO Investor Forum
11. Hyperion Therapeutics, Inc. Announces Senior Management Team and $15M Financing Event

Post Your Comments:
*Name:
*Comment:
*Email:
(Date:12/1/2009)... A new clinical study presented to the American...e-dimensional (3-D) automated ultrasound follicle ...in vitro fertilization (IVF) cycle is effective an...nt of the follicles. , Gu...Fertility Center of Chicago has just completed res...
(Date:12/1/2009)... iCardiac now provides services to three out of... Rochester, NY (PRWEB) Decembe... leader in advanced cardiac core lab services and ...aceutical company has selected iCardiac as a prefe...ll provide Highly Automated QT(sm) and Dynamic QT ...
(Date:12/1/2009)... Michael R. Drapp, a 34-year veteran of the hig...Technologies, a business development and intellect...rging nanotechnology space. The company also plan... nanotechnology incubator. , ...ael R. Drapp , a 34-year veteran of the high-techn...
(Date:11/30/2009)...ovember 30, 2009 An international team of applied... ETH Zrich have demonstrated compact, multibeam, a...le part of the light spectrum (infrared). By contr...well-defined wavelength. The innovative multibeam ...to remote chemical sensing pollution monitoring, o...
Breaking Biology Technology:Computerized IVF Follicle Measurements are Faster and Give High Success Rates, Says Research from Chicago Fertility Doctors Richard Sherbahn and Todd Deutch 2Computerized IVF Follicle Measurements are Faster and Give High Success Rates, Says Research from Chicago Fertility Doctors Richard Sherbahn and Todd Deutch 3Another Top Five Pharmaceutical Company Selects iCardiac as Preferred Provider of ECG Core Lab Services 2Silicon Valley Veteran Launches New Venture on the “nanoEdge” of the Emerging Nanotechnology Revolution 2Silicon Valley Veteran Launches New Venture on the “nanoEdge” of the Emerging Nanotechnology Revolution 3Silicon Valley Veteran Launches New Venture on the “nanoEdge” of the Emerging Nanotechnology Revolution 4Scientists demonstrate multibeam, multi-functional lasers 2
...ot chocolate present risk, OAKLAND, Calif., Jan. ...-- whether from coffee, tea, caffeinated soda or h...iage, according a new study,by the Kaiser Permanen...,the first time, pregnancy-related symptoms of nau... interfere with the determination of caffeine,s tr...
...t NNRTI to show antiviral activity in patients wit... BRIDGEWATER, N.J., Jan. 18 The U.S. Food and Dru...roval to the anti-HIV,medication INTELENCE (etravi...transcriptase inhibitor (NNRTI) to show antiviral ...with HIV resistant to a NNRTI and,other antiretrov...
...Eli Lilly and Company,strongly objects to implicat...y that the company has suppressed results of negat...ate article in The New England Journal of,Medicine...amples of how the,industry purportedly suppresses ...es, story inaccurate when it comes to Prozac -- th...
Other Biology Technology:Kaiser Permanente Study Shows Newer, Stronger Evidence That Caffeine During Pregnancy Increases Miscarriage Risk 2Kaiser Permanente Study Shows Newer, Stronger Evidence That Caffeine During Pregnancy Increases Miscarriage Risk 3Kaiser Permanente Study Shows Newer, Stronger Evidence That Caffeine During Pregnancy Increases Miscarriage Risk 4FDA Approves INTELENCE(TM) (etravirine) for HIV Combination Therapy 2FDA Approves INTELENCE(TM) (etravirine) for HIV Combination Therapy 3FDA Approves INTELENCE(TM) (etravirine) for HIV Combination Therapy 4FDA Approves INTELENCE(TM) (etravirine) for HIV Combination Therapy 5FDA Approves INTELENCE(TM) (etravirine) for HIV Combination Therapy 6FDA Approves INTELENCE(TM) (etravirine) for HIV Combination Therapy 7FDA Approves INTELENCE(TM) (etravirine) for HIV Combination Therapy 8In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement: 2In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement: 3In response to a New England Journal of Medicine article published yesterday and subsequent media coverage, Eli Lilly and Company issued the following statement: 4
(Date:11/26/2009)...d sharks are some of the Ocean,s most distinctive ...have this strange head shape, says Michelle McCom...eason is the shark,s vision. ,Perhaps their visual..., says McComb, giving the sharks excellent stereo... McComb, there were two schools of thought on this...
(Date:11/26/2009)..., Mass. (November 26, 2009) Whitehead researchers...uman cells to pinpoint specific genes and proteins...cience . , In most human cell cultures genes are...her and one from the mother. Gene inactivation by ... copy is inactivated, the second copy usually rema...
(Date:11/25/2009)...a hormone produced in the stomach, may be used to ...arkinson,s disease, Yale School of Medicine resear...e of the Journal of Neuroscience . , Parkinson,...neurons in an area of the midbrain known as the su...production. Reduced production of dopamine in lat...
Breaking Biology News(10 mins):Wide heads give hammerheads exceptional stereo view 2Knockouts in human cells point to pathogenic targets 2Hormone ghrelin can boost resistance to Parkinson's disease 2Sorenson Molecular Genealogy Foundation to Protect Archived DNA Using Biomatricas Room Temperature Storage 12936 1Sorenson Molecular Genealogy Foundation to Protect Archived DNA Using Biomatricas Room Temperature Storage 12936 2Sorenson Molecular Genealogy Foundation to Protect Archived DNA Using Biomatricas Room Temperature Storage 12936 3Meatless Burgers Hot Dogs Not Always Full of Veggies 51049 1Meatless Burgers Hot Dogs Not Always Full of Veggies 51049 2AlphaRx Reports Positive Preclinical Data on GAI 122 Against Liver Disease 51046 1AlphaRx Reports Positive Preclinical Data on GAI 122 Against Liver Disease 51046 2
...an counteract the effects of tumor-promoting molec...nvestigators at the University of Pennsylvania Sch...ers discovered that Srcasm acts like a brake in ep...h caused by a family of proteins called Src kinase...f Biological Chemistry, suggests a target for futu...
... producing special proteins that minimize environm...f intense environmental conditions in one of the w...that adult midges (Belgica antarctica) lose their ...at-shock proteins. Instead, like most animals, adu...e stressed. The discovery currently appears in the...
...young women to participate in the first U.S. study...prevent herpes and HIV infection. , If it is effec...stration, the gel would be an important weapon in ... to protect themselves from infection rather than ...e significance of the gel is that it potentially g...
Other Biology News:Signal protein shows promise for blocking tumor promoters in skin cells 2Unique gene regulation gives chilly bugs survival advantage at bottom of the world 2Unique gene regulation gives chilly bugs survival advantage at bottom of the world 3UCSF study will test new vaginal microbicide for herpes and HIV 2UCSF study will test new vaginal microbicide for herpes and HIV 3
G(5)ppp(5)G from Ambion
...gly essential for reducing sample and waste volume...ions. The eight-channel nano25 delivers with perfo... ,Features: , Real-time documented confirmation ... diagnostics detect and correct clogging, adapt to...
cAMP Competitive immunoassay Assay Kit, HTRF from Cisbio
Microtiter Wells from Bethyl Laboratories
Biology Products: